Evidence map›Paper›PMID 34178328›Full record

ArticleMolecular and clinical oncology2021

Neuroendocrine tumors in Panama: A nationwide database analysis.

Moises Cukier, Ruth Vergara, Jorge D Mendez-Rios, Omar Castillo, Irma Barrera, Eliecer Tello, Olivia El Achtar, Yong Loo, Hector Tapia, Guadalupe Perez and 1 more

Abstract read
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Role of Somatostatin Signalling in Neuroendocrine Tumours.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Moises CukierDepartment of Surgical Oncology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Ruth VergaraDepartment of Pathology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Jorge D Mendez-RiosDepartment of Genetics and Cytogenetics, Caja de Seguro Social, Panama City, Panama 0824, Republic of Panama.
Omar CastilloDepartment of Medical Oncology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Irma BarreraDepartment of Pathology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Eliecer TelloDepartment of General Surgery, Caja de Seguro Social, Panama City, Panama 0824, Republic of Panama.
Olivia El AchtarDepartment of Surgical Oncology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Yong LooDepartment of Medical Oncology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Hector TapiaDepartment of Radiology and Interventionism, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.
Guadalupe PerezDepartment of Endocrinology, Caja de Seguro Social, Panama City, Panama 0824, Republic of Panama.
Maximino PeñaDepartment of Gastroenterology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine tumors (NETs) comprise a heterogenous group of rare malignancies, which are increasing in incidence worldwide. To further understand the epidemiology of NETs in the Republic of Panama, the present study used two study groups, which included patients from several hospitals and clinics throughout the country, who were referred to the three largest national reference centers: The Complejo Hospitalario Metropolitano, Hospital Santo Tomas and Instituto Oncologico Nacional. These two groups comprised a retrospective cohort, which included cases reported between 2016 and 2017, and a second cohort, which was retrospective, but data were continuously collected from patients diagnosed with NETs between 2018 and 2019. Data from 157 patients with NETs reported that 83% of patients were in the 40-80 years old age group. The majority of cases (46%) presented as grade G1 tumors, while 29% were G3. Computerized tomography scans with contrast, and analysis of the Ki-67 biomarker and immunohistology markers (chromogranin A and synaptophysin) was performed in the majority of the cases. The results revealed that the most frequent anatomical sites for the primary tumor were the colorectum (17.2%), pancreas (12.7%) and stomach (12.1%), and the most frequent organ with metastasis was the liver, accounting for 34% of all cases. In conclusion, the present study is the first comprehensive study of NET in Panama to the best of our knowledge, which provides evidence of the demographic characteristics of the population, clinical features and overall survival for the affected population in this Central American country.

Indexed as

clinical dataepidemiologyneuroendocrine tumorsRepublic of Panama

Identifiers

PMID34178328
PMCPMC8220651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.